Breast Cancer Drug Development with Komal Jhaveri, MD

In this episode, host Shikha Jain, MD, speaks with Komal Jhaveri, MD, about breakthroughs in breast cancer treatment, where the field is evolving with anti-body drug conjugates and more. •    Welcome to another exciting episode of Oncology Overdrive 1:17 •    About Jhaveri 1:21 •    The interview 1:41 •    How did you get into this highly specialized field? […] How did you become a breast oncologist and find yourself at Memorial Sloan Kettering?  2:07 •    As a breast oncologist, what has really excited you in the breast cancer space over the last decade?  5:02 •    What do you think is going to happen in the next five to twenty years? Where do you think breast cancer treatment is going to evolve?  13:44 •    Do you think AI is going to have a big impact on how we treat patients? 17:47 •    If someone could only listen to the last minute of this episode, what would you want them to take away? 19:52 •    How to contact Jhaveri 20:34 •    Thanks for listening 21:32 Komal Jhaveri, MD, is a breast oncologist & early drug development specialist, clinical director of the early drug development service, and section head of the endocrine therapy research program at Memorial Sloan Kettering Cancer Center (MSK). We'd love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Jhaveri can be reached at her office 646-888-5157, or via email [email protected].  Disclosures: Jain reports no relevant financial disclosures. Jhaveri reports she is the principal investigator for Genentech's INAVO120 trial at MSK and co-chair globally.